Humacyte, Inc. (HUMA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors
Humacyte, Inc. (HUMA) closed at $5.70 in the latest trading session, marking a +0.53% move from the prior day.
Humacyte, Inc. (HUMA) Increases Yet Falls Behind Market: What Investors Need to Know
Humacyte, Inc. (HUMA) closed at $5.46 in the latest trading session, marking a +0.09% move from the prior day.
Humacyte: Navigating The FDA Uncertainty And ATEV's Potential
Humacyte's acellular tissue engineered vessel (ATEV) shows promise in trauma and dialysis, with positive clinical trial results and potential FDA approval by year-end. Despite FDA delays, Humacyte remains optimistic but faces financial instability, with only $43.6 million in cash, supporting operations for 1.5 quarters. HUMA stock is rated as a moderate "Buy" for high-risk tolerant investors, given the potential for FDA approval and significant market capture in trauma.
Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Humacyte's (HUMA) ATEV BLA Review Period Extended by FDA
Humacyte's (HUMA) Biologic License Application for its ATEV faces a delay as the FDA extends its review timeline, recognizing the product's potential impact on vascular trauma treatment.
Humacyte, Inc. (HUMA) Q2 2024 Earnings Call Transcript
Humacyte, Inc. (NASDAQ:HUMA ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Lauren Marek - LifeSci Advisors Laura Niklason - President and CEO Dale Sander - CFO and Chief Corporate Development Officer Conference Call Participants Ryan Zimmerman - BTIG Josh Jennings - TD Cowen & Company Allison Bratzel - Piper Sandler Kristen Kluska - Cantor Fitzgerald Bruce Jackson - The Benchmark Company Operator Good afternoon, ladies and gentlemen, and welcome to the Humacyte's Second Quarter Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
Delay Hits Humacyte's Bioengineered Human Tissue Implant For Vascular Trauma Injuries, FDA Extends Time To Review
Friday, the FDA announced it would require additional time to complete its review of Humacyte Inc.'s HUMA Biologic License Application (BLA) for the acellular tissue-engineered vessel (ATEV) in the vascular trauma indication.
US FDA extends review of Humacyte's blood vessel implant
Humacyte said on Friday the U.S. health regulator has extended review of the company's implant that can act as a replacement for an injured or damaged blood vessel, sending its shares down more than 20% after the bell.
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Humacyte, Inc. (HUMA) closed the most recent trading day at $8.29, moving -0.72% from the previous trading session.
Humacyte: Creating New Medical Frontiers With Bioengineered Human Tissue
Humacyte, a bioengineering company, went public through a SPAC merger in 2015, with a market value of $1.1 billion. The company has received FDA's RMAT designation for three indications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Humacyte's potential product, Acellular Tissue Engineered Vessel, has shown promise in addressing critical medical needs, with a pending FDA approval decision on August 10th.
Humacyte: Pioneering Vascular Solutions With High-Stakes Potential
Humacyte is developing HAVs for multiple indications, showing promising clinical outcomes, and receiving FDA RMAT designation for faster approval processes. The market for vascular repairs is large and growing, with Humacyte's HAVs positioned as a potentially superior option to traditional treatments. Financially, Humacyte holds sufficient short-term assets but faces significant long-term liabilities and a potential cash crunch within a year.
Humacyte wins special advanced-therapy designation for ATEV
Humacyte Inc (NASDAQ: HUMA) opened close to 25% up on Monday after the Food & Drug Administration granted its ATEV a special advanced-therapy designation. Shares of the biotech firm are still down some 30% versus their year-to-date high.
